Friedelin suppresses osteoclastogenesis via sequential dual-targeting of p105 processing and STAT3-mediated metabolic reprogramming
{{output}}
Background: Pathological osteolysis, driven by excessive osteoclast activity, is a hallmark of Rheumatoid Arthritis (RA) and osteoporosis. Current therapies target inflammation but fail to prevent bone erosion, highlighting the d... ...
